The Development of INT131 as a Selective PPAR Modulator: Approach to a Safer Insulin Sensitizer
Figure 8
INT131 does not increase plasma volume,
heart weight, or lung weight. Zucker
fatty rats were treated orally once daily for 14 days with 80 mg/kg/day of
INT131 or rosiglitazone (/group). (a) Hematocrit, (b) heart weight,
and (c) lung weight were measured,
and organ weights normalized to body weight. Adapted from [17, 19].
